tirzepatide and hrt together Hormone Replacement Therapy Tirzepatide, Hormone Therapy Combination Increases

In people with obesity and established cardiovascular disease but without diabetes, semaglutide 2.4 mg resulted in 20% reduction in major adverse cardiovascular events [(MACE), death from cardiovascular causes, nonfatal myocardial infarction or nonfatal stroke] compared to placebo (SELECT trial) after a mean follow-up of 39.8 months this is the first trial demonstrating cardiovascular benefit for an obesity pharmacotherapy [110]

However, these technologies are years away from potential approval for human use

Similarly, smoking can induce ROS production by increasing lipid peroxidation and reducing cellular antioxidant levels

This is one of the most sensitive echocardiographic findings for CP